Small Biotech Gets Rights to Rare Disease Drug

The NIH licensed rights to cyclodextrin to Vtesse, a biotechnology company that will take on development of the drug for the treatment of Niemann-Pick Type C disease.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news